. 2023 Aug 30;3(1):e230006. doi: 10.1530/EO-23-0006

Table 2.

Change levels before and after treatment.

Variables	Change levels (vs before αMPT administration)		P^b
Variables	After αMPT administration	After surgery	P^b
Blood pressure, mmHg (n = 10)
Systolic	−12.5 (IQR = −18.3 to −2.3)	16.0 (IQR = −29.0 to 1.75)^a	0.89^c
Diastolic	−7.5 (IQR = −11.0 to 0.3)	−8.0 (IQR = −20.0 to 4.5)^a	>0.99^c
Heart rate, bpm (n = 10)	−6.1 ± 6.5	−3.2 ± 8.9	0.26^d
Parameters for glucose metabolism (n = 8)
HOMA-β	11.4 ± 30.1	57.9 ± 42.5	0.042 ^d
ΔCPI	0.65 (IQR = −0.48 to 0.95)	0.40 (IQR = −0.95 to 1.07)^a	0.74^c
HOMA-R	−0.40 ± 0.64	−0.18 ± 0.70	0.41^d

Normally distributed variables and non-normally distributed variables are presented as the mean ± s.d. and the median (interquartile range), respectively. ^aNormally distributed variables; however, presented as median (interquartile range) to compare with non-normal distributed variables.^bP for significance between two groups (before to after metyrosine (αMPT) administration) and (before treatment to after surgery). ^cP-values were analyzed using the Wilcoxon’s signed-rank test. ^dP-values were analyzed using a paired t-test. P-values of <0.05 are considered significant (bold).

αMPT, α-methyl-para-tyrosine (metyrosine); bpm, beats per min; CPI, C-peptide index; HOMA-β, homeostasis model assessment of β-cell function; HOMA-R, homeostasis model assessment of insulin resistance.